According to new research published today in the American Heart Association's flagship journal Circulation, women face a 20% increased risk of developing heart failure or dying within five years after their first severe heart attack compared with...
Moderna today announced that the primary efficacy analysis of their Phase 3 study of their vaccine candidate, mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The data analysis indicates a...
Northwestern University researchers have developed a new artificial intelligence (A.I.) platform that detects COVID-19 by analyzing X-ray images of the lungs.
Called DeepCOVID-XR, the machine-learning algorithm outperformed a team of specialized thoracic radiologists --...
A third COVID-19 vaccine, this one from AstraZeneca, reported Monday that late-stage trials showed that its COVID-19 vaccine with Oxford University was up to 90% effective in preventing disease.
The results are based on...
Pfizer Inc. and its German partner, BioNTech SE will submit a request today to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of their mRNA vaccine candidate, BNT162b2 against SARS-CoV-2, which will potentially enable...
In a press release issued today, Pfizer said that new test results show its coronavirus vaccine is 95% effective, is safe and also protects older people most at risk of dying — the last data needed to...
Updated data from researchers at John Hopkins University showed 143,200 cases were added on Wednesday, topping the record set the day before by almost 3,000 cases. Wednesday was the fifth single-day case record in nine days.
In a note to clients Tuesday, SVB Leerink analyst Geoffrey Porges said
the recent results from Pfizer's early COVID-19 vaccine data should “boost
confidence of the general public in COVID vaccines, which should drive up the
early adoption rate.” The analysts see Pfizer’s...
President-elect Joe Biden hit the ground running Monday morning with an announcement of his transition team’s COVID-19 advisory board. The advisory board will be co-chaired by public health experts including Rick Bright, a vaccine expert and the former...
Pfizer and its partner BioNTech, has released promising interim data from the Phase III COVID-19 vaccine trial. The data suggest a 90% efficacy rate for the vaccine.
Initially, the plan was to conduct...
Quicken Inc., maker of America's best-selling personal finance software, today shared findings from a survey that explored Americans' financial outlook amid the...
